8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 20, 2016)

Filed July 20, 2016For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on July 20, 2016, to report its second quarter 2016 results of operations. The filing primarily directs investors to a press release (Exhibit 99.1) that contains the detailed financial results and management's commentary. A key takeaway is Abbott's use of non-GAAP financial measures to provide a clearer view of ongoing business performance, excluding items such as foreign exchange impacts (specifically mentioning Venezuela), cost reduction initiatives, transaction costs, and certain tax resolutions. Investors should note that the company emphasizes these non-GAAP measures as supplemental information to GAAP-based reporting, designed to offer greater visibility into operational performance as assessed internally by management. The report highlights the company's approach to financial reporting, aiming to assist investors in evaluating underlying business trends beyond the impact of extraordinary or non-recurring items.

Key Highlights

  • 1Abbott Laboratories reported its Q2 2016 financial results via an 8-K filing on July 20, 2016.
  • 2The primary disclosure is a press release (Exhibit 99.1) containing the detailed Q2 2016 earnings announcement.
  • 3Abbott utilizes non-GAAP financial measures to present operational results, excluding specified items.
  • 4Items excluded from non-GAAP measures include foreign exchange losses (notably Venezuela), cost reduction initiatives, transaction costs, and tax-related items.
  • 5The company states that non-GAAP measures provide better visibility into ongoing business performance and are used internally by management.
  • 6Investors are advised to consider non-GAAP measures alongside GAAP measures, not as a substitute.
  • 7The CFO, Brian B. Yoor, signed the filing, indicating executive-level review.

Frequently Asked Questions

The main purpose of this 8-K filing is to report Abbott Laboratories' financial results for the second quarter of 2016. It includes a press release that details the company's operational and financial performance for the period.

Abbott uses non-GAAP financial measures to provide investors with a clearer view of its ongoing business performance by excluding certain items that are considered unusual or unpredictable. Examples include foreign exchange losses (specifically mentioning Venezuela), costs associated with cost reduction initiatives, transaction-related costs, and the resolution of various tax positions.

No, Abbott's management advises investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). The non-GAAP measures are intended to offer supplemental insights into performance.

The detailed Q2 2016 results are provided in the press release, which is included as Exhibit 99.1 to this 8-K filing. This press release is incorporated by reference into the report.